HCWB
HCW Biologics Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.23
−0.81%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.26
From 52W high−94.86%
Volume98003.00
Market cap$2.75M
P/E (TTM)—
P/S (TTM)0.4x
Div yield—
Key dataOct 19, 2026
Open
$1.26
From 52W high
−94.86%
Volume
98003.00
Market cap
$2.75M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.0x
P/E (TTM)
—
RSI (14)
28.5
MomentumView details →
1D Return
−0.81%
YTD Return
−78.69%
SummaryUpdated Jun 1, 2026
HCW Biologics Inc. (NASDAQ:HCWB) is a preclinical-stage biopharmaceutical company founded in 2018 and headquartered in Miramar, Florida. The company went public in July 2021 and focuses on developing novel immunotherapies targeting chronic, low-grade inflammation and age-related diseases. HCW Biologics operates in the highly specialized field of cancer immunotherapy and autoimmune disease treatment, with a pipeline of experimental drugs in various stages of development from preclinical research to Phase II clinical trials.
Similar companies
Latest newsMore news →
HCW Biologics Inc. announced the pricing of a $1.5 million private placement with an existing stockholder.26d agoHCW Biologics signed an exclusive distribution agreement with Akron Biotech to commercialize HCW11-006 as a reagent to support the production of highly functional human CAR-T cells.42d ago